GCFRX
Price
$10.30
Change
+$0.01 (+0.10%)
Updated
Jun 2 closing price
Net Assets
237.33M
VASIX
Price
$16.14
Change
+$0.02 (+0.12%)
Updated
Jun 2 closing price
Net Assets
4.03B
Interact to see
Advertisement

GCFRX vs VASIX

Header iconGCFRX vs VASIX Comparison
Open Charts GCFRX vs VASIXBanner chart's image
GCFRX vs VASIX Comparison Chart in %
View a ticker or compare two or three
VS
GCFRX vs. VASIX commentary
Jun 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GCFRX is a StrongBuy and VASIX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VASIX has more cash in the bank: 4.03B vs. GCFRX (237M). VASIX pays higher dividends than GCFRX: VASIX (3.48) vs GCFRX (3.22). GCFRX was incepted earlier than VASIX: GCFRX (23 years) vs VASIX (32 years). GCFRX (1.21) is less costly to investors than VASIX (0.10). GCFRX is a more actively managed with annual turnover of: 32.77 vs. VASIX (8.00). GCFRX has a lower initial minimum investment than VASIX: GCFRX (0) vs VASIX (3000). GCFRX (8.65) and VASIX (8.44) have marching annual gain over last year. GCFRX return over 5 years is better than : 7.77 vs. VASIX (5.73).
GCFRXVASIXGCFRX / VASIX
Total Expense Ratio1.210.101,210%
Annual Report Gross Expense Ratio1.210.101,210%
Fund Existence23 years32 years-
Gain YTD2.9192.94899%
Front LoadN/AN/A-
Min. Initial Investment03000-
Min. Initial Investment IRAN/AN/A-
Net Assets237M4.03B6%
Annual Yield % from dividends3.223.4892%
Returns for 1 year8.658.44103%
Returns for 3 years17.9918.8995%
Returns for 5 years7.775.73136%
Returns for 10 years27.6333.1983%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ALL210.463.25
+1.57%
Allstate Corp (The)
GSHR10.40N/A
N/A
Gesher Acquisition Corporation II
MAIN51.57-0.04
-0.08%
Main Street Capital Corp
MLKN15.06-0.33
-2.11%
MillerKnoll
NCEL3.32-0.16
-4.60%
NewcelX Ltd.